Browse > Article
http://dx.doi.org/10.13048/jkm.22032

The effect of isoflavonoid contents in SH003 and its subfractions on breast cancer  

Yu-Jeong Choi (Department of Science in Korean Medicine, Graduate School, Kyung Hee University)
Won-Geun Choi (Department of Science in Korean Medicine, Graduate School, Kyung Hee University)
Kangwook Lee (Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University)
Miso Jeong (Department of Science in Korean Medicine, Graduate School, Kyung Hee University)
Sang Cheol Park (Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University)
Young Pyo Jang (Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee University)
Seong-Gyu Ko (Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University)
Publication Information
The Journal of Korean Medicine / v.43, no.3, 2022 , pp. 79-93 More about this Journal
Abstract
Objectives: We investigated the isoflavone contained in SH003 and its fractions, and the effect of these components on the inhibition of breast cancer. Methods: The isoflavones in solvent fractions of SH003 extract were identified by UPLC-MS and its contents were quantified using HPLC analysis. The estrogenic activity of SH003 or fractions was assessed by ERE luciferase assay in estrogen receptor (ER)-positive MCF-7 cells. To test the breast cancer inhibitory effect, the cell viability was measured using an MTT assay. Results: In this study, we demonstrated that SH003 and fractions contain 4 isoflavones which are calycosin-7-β-D-glucoside, formononetin-7-β-D-glucoside, calycosin, and formononetin. Despite containing isoflavones, estrogen-dependent transcription activity was not altered by both SH003 and fractions. On the other hand, SH003 and fractions inhibited the cell viability of breast cancer. In addition, its isoflavone components also showed reduced cell viability in various breast cancer cells. Conclusions: Overall, the phytoestrogen included in SH003 and fractions did not influence the estrogenic activity, emphasizing the safety of SH003 and fractions in breast cancer treatment.
Keywords
SH003; fractions; isoflavone; phytoestrogen; anti-cancer effect; breast cancer;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Chen, J., Zhang, X., Wang, Y., Ye, Y. & Huang, Z. Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERalpha. Mol Carcinog 57, 817-830, doi:10.1002/mc.22531 (2018).   DOI
2 Li, S. et al. Anti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: Status and prospect. J Ethnopharmacol 258, 112797, doi:10.1016/j.jep.2020.112797 (2020).   DOI
3 Zhang, J. et al. Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds. Anticancer Agents Med Chem 12, 1239-1254, doi:10.2174/187152012803833071 (2012).   DOI
4 Zhang, J. et al. Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells. J Ethnopharmacol 221, 91-99, doi:10.1016/j.jep.2018.04.014 (2018).   DOI
5 Kweon, B. et al. Effect of Angelica gigas Nakai Ethanol Extract and Decursin on Human Pancreatic Cancer Cells. Molecules 25, doi:10.3390/molecules25092028 (2020).   DOI
6 Minh, C. V. et al. Chemical constituents of Trichosanthes kirilowii and their cytotoxic activities. Arch Pharm Res 38, 1443-1448, doi:10.1007/s12272-014-0490-6 (2015).   DOI
7 Choi, Y. J. et al. SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med 16, 507, doi:10.1186/s12906-016-1490-5 (2016).   DOI
8 Choi, Y. K. et al. Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm 2014, 492173, doi:10.1155/2014/492173 (2014).   DOI
9 Kim, T. W., Cheon, C. & Ko, S. G. SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells. Cell Death Dis 11, 717, doi:10.1038/s41419-020-02924-w (2020).   DOI
10 Jeong, M. S. et al. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. Int J Mol Sci 22, doi:10.3390/ijms22168405 (2021).   DOI
11 Han, N. R. et al. The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin. J Ethnopharmacol 285, 114893, doi:10.1016/j.jep.2021.114893 (2022).   DOI
12 Keinan-Boker, L., van Der Schouw, Y. T., Grobbee, D. E. & Peeters, P. H. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 79, 282-288, doi:10.1093/ajcn/79.2.282 (2004).   DOI
13 Lee, K. et al. Herbal Prescription SH003 Alleviates Docetaxel-Induced Neuropathic Pain in C57BL/6 Mice. Evid Based Complement Alternat Med 2021, 4120334, doi:10.1155/2021/4120334 (2021).   DOI
14 Lumachi, F., Brunello, A., Maruzzo, M., Basso, U. & Basso, S. M. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 20, 596-604, doi:10.2174/092986713804999303 (2013).   DOI
15 Sasaki, Y. et al. [Complementary and Alternative Medicine for Breast Cancer Patients: An Overview of Systematic Reviews]. Yakugaku Zasshi 139, 1027-1046, doi:10.1248/yakushi.18-00215 (2019).   DOI
16 Adlercreutz, H. Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol 83, 113-118, doi:10.1016/s0960-0760(02)00273-x (2002).   DOI
17 Choi, Y. K. et al. SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget 8, 88386-88400, doi:10.18632/oncotarget.11393 (2017).   DOI
18 Choi, E. K. et al. SH003 selectively induces p73dependent apoptosis in triplenegative breast cancer cells. Mol Med Rep 14, 3955-3960, doi:10.3892/mmr.2016.5722 (2016).   DOI
19 Woo, S. M. et al. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer. Phytother Res 30, 1817-1823, doi:10.1002/ptr.5687 (2016).   DOI
20 Choi, Y. J. et al. SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer. Biomed Res Int 2022, 3647900, doi:10.1155/2022/3647900 (2022).   DOI
21 Tanwar, A. K., Dhiman, N., Kumar, A. & Jaitak, V. Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. Eur J Med Chem 213, 113037, doi:10.1016/j.ejmech.2020.113037(2021).   DOI
22 Yu, H. et al. Optimizing combinations of flavonoids deriving from astragali radix in activating the regulatory element of erythropoietin by a feedback system control scheme. Evid Based Complement Alternat Med 2013, 541436, doi:10.1155/2013/541436 (2013).   DOI
23 McGrowder, D. A. et al. Medicinal Herbs Used in Traditional Management of Breast Cancer: Mechanisms of Action. Medicines (Basel) 7, doi:10.3390/medicines7080047 (2020).   DOI
24 Hsieh, C. J., Hsu, Y. L., Huang, Y. F. & Tsai, E. M. Molecular Mechanisms of Anticancer Effects of Phytoestrogens in Breast Cancer. Curr Protein Pept Sci 19, 323-332, doi:10.2174/1389203718666170111121255 (2018).   DOI
25 Micek, A. et al. Dietary phytoestrogens and biomarkers of their intake in relation to cancer survival and recurrence: a comprehensive systematic review with meta-analysis. Nutr Rev 79, 42-65, doi:10.1093/nutrit/nuaa043 (2021).   DOI